When administrated by isolated limb perfusion, tumor necrosis factor a (TNFa) is an efficient antitumor agent that improves drug penetration and destroys angiogenic vessels. Moreover, the pronounced potentiation of TNFainduced apoptosis by NF-jB inhibitors suggest that these compounds could enhance TNFa antitumor efficacy through direct induction of tumor cell apoptosis. Therefore, attempts at amplifying signaling pathways that mediate TNFa antitumor effects could help to design combination therapies improving its efficiency. We report that nanomolar concentrations of all-trans retinoic acid (ATRA) amplify TNFa-induced apoptosis in APL cells expressing a specific repressor of NF-jB activation. This effect is abolished by the pan-caspase inhibitor, Z-VADfmk and by caspase-8 and -9 inhibitors. Cell death is accompanied by a drop of mitochondrial potential and by poly (ADP-ribose) polymerase (PARP) activation. Using specific PARP-1 inhibitors and siRNAs, we show that PARP-1 is essential for the synergistic apoptotic effect and c-Jun N-terminal kinase 1 (JNK1) activation triggered by the ATRA/TNFa combination. JNK1 siRNAs reduce ATRA/TNFa-induced apoptosis, mitochondrial release of cytochrome c and caspase-9 activation. Altogether, these results identify a novel mechanism of PARP-1-induced apoptosis, in which JNK1 provides a link between PARP-1 activation and mitochondrial pathway of caspase-9 activation. This study also suggests that inclusion of nanomolar doses of ATRA could be clinically beneficial in amplifying TNFa-induced antitumor signals.
Introduction
Tumor necrosis factor a (TNFa) is a multifunctional cytokine involved in the regulation of key biological processes such as inflammatory and immunological responses, cell proliferation and apoptosis (Locksley et al., 2001) . Its ability to induce hemorrhagic necrosis of tumors was described several decades ago (Carswell et al., 1975) . However, given the severe inflammatory syndrome observed in patients treated with high doses of this cytokine, its clinical application has been limited to regional treatment of locally advanced solid tumors. Under these conditions, its use in combination with chemotherapy proved to be safe and efficient through dual targeting: increased vascular permeability and therefore penetration of anticancer agents, and subsequently vascular collapse (Lejeune and Ru¨egg, 2006; Van Horssen et al., 2006) .
Recently, several observations led to re-examination of recombinant TNFa as anticancer agents in systemic treatment of a large panel of tumor types. It was reported that TNFa-induced inflammatory syndrome can be controlled without reducing its antitumor capacity (Van Molle et al., 2002) . Also, preclinical studies revealed that it is possible to target TNFa to angiogenic vessels or to tumor cells (Lejeune and Ru¨egg, 2006) . Likewise it was shown that inactivation of the TNFa-inducible NF-kB pathway greatly potentiates the cytotoxic action of TNFa (Dutta et al., 2006) . Altogether, these findings revived the hope for a safe use of TNFa in anticancer protocols. Such protocols should benefit from approaches aimed at amplifying TNFainduced signaling pathways that mediate its antitumor effects.
TNFa acts through two distinct cell surface receptors, TNF receptor 1 (TNF-R1) and TNF receptor 2 (TNF-R2). TNF-R2 is expressed only on hematopoietic and endothelial cells, while TNF-R1 is expressed on all cell types and initiates the majority of TNFa biological activities. The major difference between the two receptors is the presence of a death domain (DD) on TNF-R1, which confers it the ability to induce apoptosis. Binding of TNFa to TNF-R1 triggers recruitment of a number of cytoplasmic signaling proteins to the intracellular moiety of the receptor (Micheau and Tschopp, 2003; Van Horssen et al., 2006) . By its interaction with TNF receptor-associated death domain (TRADD), TNF-R1 recruits the cytoplasmic adaptor protein Fas-associated death domain (FADD) , which on its turn recruits caspase-8, a key initiator of apoptosis. TRADD also recruits TRAF-2 and the protein kinase RIP, which results in initiation of pathways that culminate in activation of transcription factors (NF-kB, c-Jun, c-Fos, ATF-2) via the activation of various kinases: IkB kinase (IKK) and MAP kinases (c-Jun N-terminal kinase 1 (JNK), p38 and ERK). These pathways control the inducible expression of genes important for the various biological functions of TNFa.
The outcomes of TNFa signaling largely depend on the cellular context. As mentioned above, in most cell types, TNFa-induced apoptotic effect is greatly enhanced when NF-kB activation is impaired. Moreover, TNFa was shown to synergize with various compounds. For example, it cooperates with interferon-g for altering endothelial cell monolayer integrity (Ruegg et al., 1998) and triggering apoptosis of tumor cells (Suk et al., 2001; Abadie et al., 2004) . Also, combination of TNFa with all-trans retinoic acid (ATRA) was shown to induce a synergistic activation of hematopoietic differentiation (Tobler et al., 1987; Witcher et al., 2003) . These studies demonstrate the possibility to influence and amplify TNFa action by converging signaling triggered by other molecules.
In the present study, we investigated whether ATRA can potentiate the rapid apoptotic effect of TNFa that is observed when NF-kB activation is impaired. Using cells carrying a specific repressor of NF-kB activation, we found that nanomolar concentrations of ATRA amplified TNFa-induced apoptosis. We demonstrate that poly (ADP-ribose) polymerase (PARP)-1 is an essential mediator of this synergistic apoptotic response. We also uncovered a novel cascade of events that leads to caspase-dependent cell death through PARP-1-mediated JNK1 activation.
Results

ATRA amplifies the apoptotic signal triggered by TNFa
Although most studies have shown a protective effect of NF-kB toward apoptosis, activation of this transcription factor has been associated with cell death in a few cellular contexts (Dutta et al., 2006) . Therefore, before investigating the ability of ATRA to amplify the cytotoxic effect of TNFa, we first analysed whether NB4 cells (an in vitro cellular model for acute promyelocytic leukemia (APL); Lanotte et al., 1991) are sensitized to TNFa-induced apoptosis, when NF-kB activation is impaired. For this purpose, we used NB4 cells expressing a specific repressor of NF-kB activation (NB4/GFP-MAD cells). This repressor, IkBa(A32/36), which is a degradation resistant form of the NF-kB inhibitor IkBa, inhibits TNFa-induced NF-kB activation (Traenckner et al., 1995; Mathieu et al., 2005) . As shown in Figures 1a and b , control NB4/GFP cells are resistant to TNFa-induced apoptosis with only 2% of the cells showing apoptotic nuclear morphology after an 18 h treatment with 60 U ml À1 of the cytokine. This percentage was strongly increased in similarly treated NB4/GFP-MAD cells, thus clearly demonstrating that NF-kB antagonizes TNFa-induced cell death in NB4 cells.
In order to establish whether ATRA could modulate the cellular apoptotic response to TNFa, a co-treatment with both compounds was performed. While ATRA had no effect by itself on cell viability, we observed that nanomolar concentrations (1 or 10 nM) of this compound potentiated TNFa-induced cell death of NB4/ GFP-MAD cells (Figures 1a and b) .
To investigate whether the ATRA-mediated potentiation of TNFa-induced apoptosis also occurs in other cell lines, the Ewing sarcoma-derived cells EW7 and the breast cancer cells MCF7 were used. We previously reported that EW7 cells carrying the NF-kB repressor (EW7-MAD cells) were greatly sensitized to the apoptotic effect of TNFa as compared to control EW7 cells (Javelaud et al., 2000) . As shown in Figure 1c , ATRA amplified TNFa-induced apoptosis of EW7-MAD cells. The effect of a combined treatment with ATRA and TNFa versus TNFa alone was also investigated in MCF7 cells following siRNA-mediated knockdown of p65, a member of the NF-kB complex. The two p65 specific siRNAs we used strongly reduced p65 expression (Figure 1d , upper) and sensitized MCF7 to TNFa-induced apoptosis (Figure 1d, lower) . Here again, we observed that the apoptotic effect of TNFa was amplified by ATRA, showing that this effect of ATRA is not limited to NB4 cells but is a more general phenomenon.
The ability of ATRA to synergize with other death receptor ligands was also investigated. In the three cell lines, no potentiation by ATRA of TRAIL-induced apoptosis was observed (Figures 1b-d) . FasL was effective at inducing apoptosis only in EW7 cells, and ATRA did not enhance this effect (Figure 1c) . We conclude that ATRA specifically amplifies TNFainduced apoptotic signaling.
ATRA amplifies TNFa-induced activation of caspases and drop of mitochondrial membrane potential It was previously reported that ATRA treatment can result in an upregulation of TNFa receptors expression (Manna and Aggarwal, 2000) . In the present study, we did not observe any modulation of surface TNF-R1 or TNF-R2 expression after treatment of NB4/GFP-MAD cells with TNFa, ATRA or TNFa þ ATRA (not shown). Therefore it appears that amplification of TNFa-induced apoptotic signal by ATRA occurs at a step downstream of the binding of TNFa to its receptors.
We then investigated whether ATRA potentiates TNFa-induced cell death through a caspase-dependent mechanism. The pan-caspase inhibitor Z-VAD-fmk completely abrogated apoptosis of both TNFa-and TNFa/ATRA-treated cells (Figure 2a ). Western blot analysis revealed that an 8 h co-treatment of NB4/ GFP-MAD cells with TNFa þ ATRA resulted in a synergistic activation of caspase-8, the initiator caspase in death receptor-induced cell death, as compared to treatment with ATRA or TNFa alone ( Figure 2b ). Caspase-8 activation did not result from a decreased expression of the caspase-8 antagonist c-Flip L since expression of c-Flip L was not modified by an 8 h ( Figure 2b ) and a 16 h (not shown) treatment with ATRA, TNFa or TNFa þ ATRA.
In addition to its ability to mediate cell death through direct activation of executor caspases, caspase-8 can trigger a mitochondria-dependent pathway of apoptosis through cleavage of Bid (Adams and Corry, 2007) . Activation of this pathway by Bid is initiated by several changes in mitochondrial function including a decrease in mitochondrial membrane potential and a release of cytochrome c and/or apoptosis inducing factor (AIF) (Garrido et al., 2006) . Interaction of released cytochrome c with ATP and APAF-1 results in activation of the initiator caspase-9, which in turn triggers activation of executor caspases (Garrido et al., 2006) . Here, we observed that an 8 h treatment of NB4/GFP-MAD cells with TNFa/ATRA resulted in synergistic caspase-9 activation and drop of mitochondrial membrane potential (Figures 2b and d) . Mitochondrial permeability transition (MPT) was shown to be a crucial event of the mitochondrial pathway of apoptosis (Garrido et al., 2006) . The participation of mitochondria in TNFa/ ATRA-induced apoptosis was further documented by the observation that cyclosporin A, a MPT inhibitor, reduced the percentage of apoptotic cells (Figure 2e ). Caspase-9 activation occurred independently of Bid cleavage since no decrease of full Bid expression could be detected in TNFa/ATRA-treated cells ( Figure 2b ) while it was clearly observed upon treatment with doxorubicin ( Figure 2c ). Activity of both caspase-8 and -9, as well as that of the executor caspase-3 was confirmed by measurement of caspases activities in living cells (Figure 2f ). In accordance with results from western blot analysis (Figure 2b ), activation of caspase-8 and -9 was already significant after an 8 h treatment with the TNFa/ATRA combination, and further increased with time of treatment ( Figure 2f ). Caspase-8, -9 and -3 participated in the TNFa/ATRA-induced apoptotic process, as revealed by the use of specific inhibitors of these enzymes (Figure 2a) . We conclude that treatment of NB4/GFP-MAD cells with the TNFa/ ATRA combination induces a caspase-dependent cell death and triggers the mitochondrial pathway of apoptosis through a mechanism that does not rely on Bid cleavage.
PARP-1 participates in the death signal triggered by a co-treatment with TNFa and ATRA Besides its essential role in DNA repair, the nuclear enzyme PARP-1 can promote mitochondrial cell death (Boulares et al., 2001; Yu et al., 2002; Nguewa et al., 2003) . We investigated the potential role of PARP-1 in cell death triggered by the combination of TNFa and ATRA. For this purpose, we first assessed PARP activation by measuring depletion of intracellular NAD(P)H which was shown to reflect PARP-1 activity (Nakamura et al., 2003) . TNFa/ATRA treatment of NB4/GFP-MAD cells increased PARP activity as compared to treatment with one of those two compounds alone (Figure 3a) , while no PARP activity was observed in similarly treated NB4/GFP cells (not shown). PARP activation was inhibited by the pan-caspase inhibitor Z-VAD-fmk (Figure 3a) , which is consistent with the role of caspase in activation of DNA fragmentation factor (DFF) that results in DNA fragmentation and PARP-1 activation (Boulares et al., 2001) . To investigate the role of PARP activity in TNFa/ATRA-induced apoptosis, two inhibitors of PARP activity, PJ-34 and DPQ, were used. Both inhibitors efficiently reduced NAD(P)H depletion ( Figure 3b ) and apoptosis (Figure 3c ) in the population of cells treated with the TNFa/ATRA combination, while no effect was observed in cells treated with TNFa alone. Furthermore, inhibition of PARP activity reduced the loss in mitochondrial potential that was observed concomitantly to the apoptotic effect (Figure 3d ), thus suggesting that PARP-1 participates in induction of mitochondrial membrane depolarization.
To further establish the participation of PARP-1 in the death signal triggered by the TNFa/ATRA combination, we used specific PARP-1 siRNAs to extinguish PARP-1 expression. The three siRNAs were very efficient at reducing this expression while control siRNAs (siGlo) had no effect (Figure 4a ). Such a reduction of PARP-1 expression correlates with a decreased sensitivity of cells to the apoptotic effect of a combined treatment with ATRA þ TNFa (Figure 4b ). PARP-1 siRNAs also reduced the loss of mitochondrial potential that accompanied the apoptotic process ( Figure 4c ). We conclude that PARP-1 participates in activation of the mitochondrial apoptotic cascade triggered by the co-treatment of cells with ATRA and TNFa. ). Also, a recent report showed that activated JNK1 provides the link between PARP-1 and mitochondria in a PARP-1-induced mitochondria-dependent cell death pathway . To investigate whether JNK1 plays a role in the synergistic apoptotic effect of the TNFa/ATRA combination, we first compared JNK activation in cells treated with TNFa, ATRA or both. For this purpose, JNK1 activation was assessed by western blot analysis using antibodies that specifically recognized JNK1 phosphorylated at threonine 183 and tyrosine 185. As shown in Figure 5a , while ATRA treatment did not result in JNK1 activation by itself, it amplified TNFa-induced activation of this kinase in NB4/GFP-MAD cells. Inhibition of PARP-1 expression by specific siRNAs resulted in inhibition of JNK1 activation by the TNFa/ATRA combination while no effect on JNK1 expression was observed (Figure 5b ). The functional significance of JNK activation in the apoptotic process was then investigated by reducing JNK1 expression with specific JNK1 siRNAs. The two siRNAs we used efficiently reduced both JNK1 activation ( Figure 6a ) and TNFa/ATRA-induced apoptosis (Figure 6b ), demonstrating that JNK1 is a component of the apoptotic pathway. A similar effect was obtained using the specific inhibitor of JNK activity, SP600125 (Figure 6c ). To examine the mechanism by which PARP-1-induced JNK1 activation participates in this pathway, the effect of JNK1 siRNAs on mitochondrial release of cytochrome c and AIF as well as on caspase-9 activation was investigated. Consistent with a role of JNK1 in a mitochondria-and caspase-dependent cell death pathway, inhibition of JNK1 activation/expression by specific siRNAs reduced mitochondrial release of cytochrome c and caspase-9 activation (Figure 6d ). Although mitochondrial release of AIF suggests that a caspase-independent apoptosis may also be part of the mechanisms leading to cell death, we conclude that in the present context of ATRA-induced amplification of TNFa signaling, PARP1-dependent JNK1 activation participates in a signaling cascade that leads to caspasedependent cell death.
Discussion
An attractive strategy for antitumor therapy includes identification of novel combinations of signaling pathways that engage tumor cells into a differentiation or apoptotic process. In the present study, we demonstrated that nanomolar concentrations of ATRA amplify TNFa-induced apoptotic signaling. We also uncovered a novel cascade of events that leads to caspase-dependent cell death through PARP-1-mediated JNK1 activation.
ATRA had no apoptotic effect by itself but amplified TNFa-induced apoptotic signaling cascade. The amplification was already detectable at an early step of this cascade, since ATRA amplified TNFa-induced caspase-8 activation, the initiator caspase of the extrinsic apoptotic pathway. The ability of ATRA to increase an apoptotic signal triggered by a death receptor ligand appeared restricted to TNFa signaling, since ATRA did not amplify TRAIL-or Fas-induced apoptosis. ATRA did not exert its effect through an enhancement of TNF-R1 expression on the cell surface or a reduction of the expression of the long isoform of the caspase-8 antagonist, c-Flip L . Therefore, the mechanisms implicated in the enhancement by ATRA of TNFa-induced apoptosis appear different from that activated by arsenic trioxide since amplification of TNFa apoptotic effect by this compound was recently shown to involve both stimulation of TNF-R1 expression and downregulation of c-Flip L levels (Amran et al., 2007) . One possibility is that ATRA specifically enhances TNFa apoptotic signal by facilitating the recruitment at the intracellular portion of TNF-R1 of adaptor proteins that precedes caspase-8 activation.
We observed that, besides its effect on the extrinsic pathway of apoptosis, ATRA also amplified TNFainduced apoptotic mitochondrial pathway through a mechanism that did not rely on Bid cleavage but was accompanied by PARP activation. PARP-1 is a DNArepairing enzyme that is now emerging as an important regulator of cell death. PARP enzymes are activated in response to DNA damage induced by various stimuli (Schreiber et al., 2006) . When DNA is moderately damaged, PARP-1 allows cell survival by participating in DNA repair. However, in the case of extensive DNA damage, PARP-1 overactivation induces a decrease of NAD þ and ATP levels, leading to cell death. The type of cell death seems to be dictated by the amplitude of PARP-1-induced decrease of ATP levels (Nguewa et al., 2003) . Apoptosis, which is an energy-requiring process, occurs when ATP loss is limited. When ATP depletion reaches a certain threshold, cells die by necrosis. In the present study, we observed that pharmacological inhibition of PARP activity or reduction of PARP-1 expression using specific siRNAs decreased TNFa/ ATRA-induced apoptosis, thus establishing the participation of this enzyme in the observed apoptotic process.
Depending on the death inducer, PARP-1-mediated apoptosis was reported to depend on either caspasedependent or caspase-independent pathways. PARP-1 activation was shown to contribute to caspase-3 activation and cytochrome c release from mitochondria in TNFa-treated fibroblasts (Boulares et al., 2001) . On the other hand, the caspase-independent cell death observed in a mouse embryonic fibroblast cell line treated with the PARP activator N-methyl-N 0 -nitro-N-nitrosoguanidine (MNNG) relied on mitochondrial depolarization and translocation of AIF from mitochondria to the nucleus (Yu et al., 2002) . In this context of cell killing that did not rely on caspase activity, the MAP kinase JNK1 was recently shown to make the link between activation of nuclear PARP-1 and mitochondria . In contrast with this role of JNK1 in a caspase-independent apoptotic process, several previous reports had associated JNK1 with caspase-dependent cell death (De Smaele et al., 2001; Javelaud and Besanc¸on, 2001; Tang et al., 2001; Kamata et al., 2005; Mathieu et al., 2005; Mathieu and Besanc¸on, 2006) . In the present study, we showed that the synergistic apoptotic process triggered by a co-treatment of NB4/GFP-MAD cells with TNFa and ATRA was caspase dependent. An amplification of TNFa-induced JNK1 activation by ATRA was observed and inhibition of TNFa/ATRA-induced apoptosis by PARP-1 siRNAs was accompanied by a reduction in JNK1 activation. In turn, siRNAsmediated reduction of JNK1 expression reduced mitochondrial cytochrome c release, caspase-9 activation and apoptosis. The fact that the observed inhibition was only partial suggests that other pathways may also be implicated. Altogether, these results demonstrate that in the context of TNFa/ATRA treatment of NB4/GFP-MAD cells, PARP-1-mediated JNK1 activation participates in a mitochondrial pathway of caspase-dependent apoptosis (Figure 7) . We conclude that the outcome, either caspase-dependent or caspase-independent cell death, of PARP-1 mediated JNK1 activation is highly stimulus dependent. Regulation of JNK1 signaling involves scaffold proteins that assemble JNK1 with other proteins into modules, the composition of which depends on tissue type or nature and duration of the upstream signal (Whitmarsh et al., 1998; Kukekov et al., 2006; Weston and Davis, 2007) . It also includes modifications by protein phosphatases and ubiquitin ligases (Kamata et al., 2005; Laine and Ronai, 2005) . These regulatory mechanisms elicit signaling toward selected downstream targets, explaining the diversification of cellular responses that may result from JNK1 activation.
We have previously reported that impairment of NFkB activation does not impede ATRA-induced differentiation of APL cells (Mathieu et al., 2005) . It has also been shown that TNFa and ATRA cooperate to induce differentiation of these cells (Witcher et al., 2003) . Therefore we propose that in the presence of an inhibitor of NF-kB, therapeutic protocols including nanomolar concentrations of ATRA and moderate concentrations of TNFa could constitute an interesting strategy for the treatment of APL. It would have the advantage of triggering two anticancer responses: a rapid apoptotic response for most of the cells and later a differentiation response of cells which could have escaped from apoptosis. We also observed that the ability of ATRA to amplify the apoptotic effect of TNFa is not cell specific, since the same effect was observed in Ewing sarcoma and breast cancer-derived cells. Therefore, in solid tumors also, combination of an NF-kB inhibitor with TNFa and nanomolar doses of ATRA should allow to decrease to a large extent the concentration of TNFa necessary to obtain an apoptotic response and consequently to reduce its side effects. We propose that such treatment would amplify the antitumoral response to TNFa by combining its effects on angiogenic vessels with direct induction of tumor cells apoptosis.
Materials and methods
Reagents
Recombinant TNFa (specific activity: 1.1 Â 10 8 U mg
À1
) and caspase inhibitors were from RD Systems (Lille, France). Alltrans retinoic acid, doxorubicin, cyclosporin A and PJ-34 were from Sigma-Aldrich (St Quentin Fallavier, France). The JNK inhibitor SP600125 was purchased from Biomol (Plymouth Meeting, PA, USA). DPQ and MitoTracker Red CMXRos were from Alexis (Illkirch, France) and Molecular Probes (Cergy Pontoise, France), respectively.
Cells
Construction of NB4/GFP-MAD cells and EW7-MAD cells expressing the NF-kB super-repressor IkBa(A32/36) was previously described (Javelaud et al., 2000; Mathieu et al., 2005) . These cells, as well as parental NB4 and EW7 cells, were grown in RPMI 1640 medium supplemented with 10% decomplemented fetal calf serum (Invitrogen, Cergy Pontoise, France). MCF7 cells (from ATCC, Manassas, VA, USA) were grown in Dulbecco's modified Eagle's medium with 10% decomplemented fetal calf serum.
Apoptosis assay
Apoptosis was assessed by microscopic observation of nuclear morphological changes characteristic of apoptosis (condensation and fragmentation) after staining with Hoechst 33258 fluorescent dye (Sigma-Aldrich). An average of 300 cells were examined for each point. Variation of the mitochondrial membrane potential (DCm) was studied using the cell permeant MitoTracker red CMXRos, a compound that accumulates in active mitochondria under the influence of DCm. Cells were incubated with 100 nM CMXRos for 30 min at 37 1C and subjected to flow cytometry analysis.
Transfection of small interfering RNAs
The siRNAs targeting PARP-1, JNK1 or p65 and the stable, nontargeting control RISC-free siGLO siRNA were purchased from Dharmacon (Perbio Science, Berbie`res, France). The sense strand nucleotide sequences of the various targeting siRNAs were as follow: PARP-1 siRNA-1, 5 0 -GAAAGUGU GUUCAACUAAUUU-3 0 (exon 6); PARP-1 siRNA-2, 5 0 -GCAACAACUGGAACAGAUUU-3 0 (exon 13); PARP-1 siRNA-3, 5 0 -GAAGUCAUCGAUAUCUUUAUU-3 0 (exon 18); JNK1 siRNA-1, GAACCAAGAAUGGAGUUAUUU-3 0 (exon 10); JNK1 siRNA-2, ACAGAGAGCUAGUUC UUAUUU-3 0 (exon 2); p65 siRNA-1, 5 0 -UUACGUUUCUC CUCAAUCCUU-3, (exon 10); p65 siRNA-2, 5 0 -UUUCCUA CAAGCUCGUGGGUU-3 0 (exon 5). NB4 or MCF7 cells (3,5 Â 10 6 cells in 0.5 ml Opti-MEM (Invitrogen) were mixed either with 0.125 nmol of nonspecific control siGlo siRNA or siRNAs against PARP-1, JNK1 or p65 and electroporated (260 V; 1050 mF). Cells were treated with ATRA, TNFa or both, 48 or 72 h later. They were then harvested for Hoechst staining, DCm measurement and immunoblotting at times indicated in the Figure Legends .
Flow cytometry analysis of caspase activation in intact cells
Caspase-3, -8 and -9 activities were measured in living cells using caspase fluorescent assay kits (Calbiochem, San Diego, CA, USA). The fluorescent markers Red-DEVD-fmk, Red-IETD-fmk and Red-LEHD-fmk are labeled, cell-permeable inhibitors that bind irreversibly to activated caspase-3, -8 and -9, respectively. Kits were used according to the manufacturer's instructions. Briefly, 3 Â 10 5 cells were incubated for 30 min at 37 1C with the fluorescent markers, washed and the fluorescence intensity was measured by flow cytometry analysis.
Immunoblot analysis Cellular extracts were prepared and analysed by SDS-PAGE as described previously (Javelaud et al., 2000) . The following antibodies were used: monoclonal antibodies to PARP-1 (C2-10) (Alexis, France), caspase-8, clone 5F7 or caspase-9, clone 96-2-22 (Upstate, Lake Placid, NY, USA), AIF (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), cytochrome c (BD Biosciences, San Jose, CA, USA); Polyclonal antibodies to Bid, phosphorylated JNK at Thr183/Tyr185 (Cell Signaling, Danvers, MA, USA), c-FLIP (Upstate), p65 or JNK (Santa Figure 7 Model for the role of a poly (ADP-ribose) polymerase (PARP)1/c-Jun N-terminal kinase 1 (JNK1) cascade in the synergistic activation of apoptosis by tumor necrosis factor a (TNFa) and all-trans retinoic acid (ATRA). In NB4 cells carrying a repressor of NF-kB activation, TNFa and ATRA synergize for caspase-8 activation, which results in DNA cleavage and PARP-1 activation. Activated PARP-1 triggers JNK1 activation, which, in the context of an ATRA-mediated amplification of TNFa-induced apoptosis, results in cytochrome c release from mitochondria, caspase-9 activation and apoptosis.
Cruz). Anti-actin antibodies (ICN Biomedicals, Aurora, OH, USA) were used as a control for protein loading.
Preparation of cytosolic extracts
Mitochondria-free cytosolic extracts were obtained using digitonin-based subcellular fractionation as described previously (Adrain et al., 2001) . Plasma membrane permeabilization was checked by staining cells with 0.08% Trypan blue solution.
Measurement of PARP-1 activity PARP-1 activity was assessed by measuring intracellular NAD(P)H depletion as previously described (Nakamura et al., 2003) . A water-soluble tetrazolium salt is used to monitor the amount of NAD(P)H in living cells through its reduction to a yellow colored water-soluble formazan dye. Briefly, cells were treated with ATRA and TNFa as described in the figure legends. At times indicated, they were centrifuged and resuspended in complete medium containing 0.5 mM XTT and 20 nM 1-methoxy PMS. The amount of formazan dye was determined 4 h later by measuring absorption at 450 nM with 650 nM as the reference filter.
